Frontline treatment of epithelial ovarian cancer

Goh, Jeffrey C.; Mohan, Ganendra Raj; Ladwa, Rahul; Ananda, Sumitra; Cohen, Paul A.; Baron‐Hay, Sally

doi:10.1111/ajco.12449

Cited by 14 publications

(12 citation statements)

References 94 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adjuvant chemotherapy to be administered after surgery is determined based on the histological type and stage of the tumor [8]. Neoadjuvant chemotherapy administered in some centers and to some patients has not been shown to be superior to postoperative adjuvant chemotherapy [9]. In this study, the outcomes of patients who were followed up and treated for serous epithelial ovarian tumor in our hospital were evaluated.…”

Section: Introductionmentioning

confidence: 99%

Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases

Akgöl

Aktürk

Özaydın

et al. 2021

Aegean J Obstet Gynecol

View full text Add to dashboard Cite

Objective: To evaluate the outcomes of patients who were followed up and treated for serous epithelial ovarian tumor. Materials and Methods: This retrospective study included 260 patients who were diagnosed with serous epithelial ovarian cancer, treated and followed up at Kanuni Sultan Suleyman Training and Research Hospital between January 2002 and December 2019. Results: The mean age of the patients participated in the study was 53.4±11.6 years. Of the patients, 79.7% had advance stage and 82.4% had grade 3 tumors. The rate of complete or optimal surgery was 88.2%, while the rate of suboptimal surgery was 11.2%. While 82% of the patients received adjuvant chemotherapy, 15.7% received neoadjuvant chemotherapy. Of the patients, 80.2% had a Ca 125 value higher than 35. Despite primary cytoreductive surgery and platinum-based adjuvant chemotherapy, the recurrence rate was 66.2%, and the PFS and OS rates were 34.7±41.0 and 50.5±40.0 months, respectively. Conclusion: The majority of serous epithelial ovarian cancers are diagnosed at an advanced stage. Despite primary situ reductive surgery and subsequent platinum-based chemotherapy, the recurrence rates are quite high.

show abstract

Section: Introductionmentioning

confidence: 99%

Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases

Akgöl

Aktürk

Özaydın

et al. 2021

Aegean J Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…Despite recent intensive research on the identification of biomarkers for early detection, currently, the only clinical available blood biomarker for EOC screening is CA125, which suffers from low sensitivity and specificity [ 4 ]. The standard treatment for women with advanced stage EOC is surgical cytoreduction followed by systemic chemotherapy [ 5 ]. Recent developments on EOC targeted therapies include angiogenesis inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors [ 6 – 7 ].…”

Section: Introductionmentioning

confidence: 99%

EphA8 is a prognostic marker for epithelial ovarian cancer

Liu

Jin

et al. 2016

Oncotarget

View full text Add to dashboard Cite

EphA8 is one of the Eph receptors in the Eph/ephrin receptor tyrosine kinase (RTK) subfamily. During tumorigenesis, EphA8 is involved in angiogenesis, cell adhesion and migration. In this study, we determined the mRNA and protein expression levels of EphA8 in cancerous and normal ovarian tissue samples by quantitative reverse transcription PCR (qRT-PCR) (N = 60) and tissue microarray immunohistochemistry analysis (TMA-IHC) (N = 223) respectively. EphA8 protein levels in cancer tissues were correlated with epithelial ovarian cancer (EOC) patients’ clinical characteristics and overall survival. Both EphA8 mRNA and protein levels were significantly higher in EOC tissues than in normal or benign ovarian tissues (all P < 0.05). High EphA8 protein level was associated older age at diagnosis, higher FIGO stage, positive lymph nodes, presence of metastasis, positive ascitic fluid, and higher serum CA-125 level. High EphA8 protein level is an independent prognostic marker in EOC. We conclude that EphA8 acts as an oncogene in EOC development and progression. Detection of EphA8 expression could be a useful prognosis marker and targeting EphA8 represents a novel strategy for EOC treatment.

show abstract

“…OC is more frequently diagnosed at an advanced stage because of the lack of efficient screening measures [ 2 , 3 ]. And the advanced stages prognosis (FIGO stage III and IV) is extremely poor with 5-year survival rates of approximately 39 and 17%, respectively [ 4 ]. The standard treatment of OC involves cytoreductive surgery and platinum-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer

Bai

Jin

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background Ovarian cancer (OC) is a gynecological malignancy with the highest mortality rate. Cisplatin (DDP) based chemotherapy is a standard strategy for ovarian cancer. Despite good response rates for initial chemotherapy, almost 80% of the patients treated with DDP based chemotherapy will experience recurrence due to drug-resistant, which will ultimately result in fatality. The aim of the present study was to examine the pathogenesis and potential molecular markers of cisplatin-resistant OC by studying the differential expression of mRNAs and miRNAs between cisplatin resistant OC cell lines and normal cell lines. Methods Two mRNA datasets (GSE58470 and GSE45553) and two miRNA sequence datasets (GSE58469 and GSE148251) were downloaded from the Gene expression omnibus (GEO) database. Differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were screened by the NetworkAnalyst. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were conducted to analyze the biological functions of DEGs. The protein-protein interaction network was constructed using STRING and Cytoscape software to identify the molecular mechanisms of key signaling pathways and cellular activities. FunRich and MiRNATip databases were used to identify the target genes of the DEMs. Results A total of 380 DEGs, and 5 DEMs were identified. Protein–protein interaction (PPI) network of DEGs containing 379 nodes and 1049 edges was constructed, and 4 key modules and 24 hub genes related to cisplatin-resistant OC were screened. Two hundred ninety-nine target genes of the 5 DEMs were found out. Subsequently, one of these 299 target genes (UBB) belonging to the hub genes of GSE58470 and GSE45553 was identified by MCODE and CytoHubba,which was regulated by one miRNA (mir-454). Conclusions One miRNA–mRNA regulatory pairs (mir-454-UBB) was established. Taken together, our study provided evidence concerning the alteration genes involved in cisplatin-resistant OC, which will help to unravel the mechanisms underlying drug resistant.

show abstract

Frontline treatment of epithelial ovarian cancer

Cited by 14 publications

References 94 publications

Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases

Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases

EphA8 is a prognostic marker for epithelial ovarian cancer

Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer

Contact Info

Product

Resources

About